Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms

Journal of Neuro-Oncology

Volumn 46, Issue 1, 2000, Pages 81-90

  Jäälinojä, Juha ^a   Herva, Riitta ^a   Korpela, Merja ^a   Höyhtyä, Matti ^b   Turpeenniemi Hujanen, Taina ^a,c  

^a UNIVERSITY OF OULU   (Finland)

^b Diabor Oy   (Finland)

^c NONE   (Finland)

Author keywords

72 kD type IV collagenase; Brain tumor; Gelatinase A; Invasion; Prognosis

Indexed keywords

GELATINASE A;

ARTICLE; ASTROCYTOMA; BRAIN CORTEX LESION; BRAIN TUMOR; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MENINGIOMA; OLIGODENDROGLIOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; BRAIN NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; STAINING AND LABELING; SURVIVAL ANALYSIS;

EID: 0742331383     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006421112839     Document Type: Article

References (53)

1. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250, 1993
2. Corcoran ML, Hewitt RE, Kiemer DE Jr., Stetler-Stevenson WG: MMP-2: Expression, activation and inhibition. Enzyme Protein 49: 7-19, 1996
3. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kD type IV collagenase. Isolation of the activated form of membrane metalloproteinase. J Biol Chem 270: 5331-5338, 1995
4. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991
5. Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A, Tryggvason K: Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 69: 312-321, 1993
6. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y, Sugimachi K: Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 17: 2253-2258, 1997
7. Grigioni WF, Garbisa S, D'errico A, Baccarini P, Stetler-Stevenson WG, Liotta LA, Mancini AM: Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 138: 647-654, 1991
8. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72,000 type TV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991
9. Margulies IMK, Höyhtyä M, Evans C, Liotta LA, Stetler-Stevenson WG: Urinary type TV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epid Biomark Preven 1: 467-474, 1992
10. Monteguado C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of type TV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136: 585-592, 1990
11. Pyke C, Ralfkiär E, Huhtala P, Hurskainen T, Danø K, Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52: 1336-1341, 1992
12. Stearns ME, Wang M: Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53: 878-883, 1993
13. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66: 1188-1194, 1992
14. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y: Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81: 69-77, 1994
15. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama JI: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298-307, 1995
16. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res 53: 2208-2211, 1993
17. Rao JS, Yamamoto M, Mohanam S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE: Expression and localisation of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14: 12-18, 1996
18. Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS: Expression and localisation of 72 kDa type TV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14: 35-42, 1996
19. Saxena A, Robertson JT, Kufta C, Stetler-Stevenson WG, Ali IU: Increased expression of gelatinase A and TIMP-2 in primary human glioblastomas. Int J Oncol 7: 469-473, 1995
20. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, deNictolis M, Garbisa S, Masiero L, Romanini C, Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995
21. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379-2387, 1996
22. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998
23. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998
24. Bjerkvig R, Lund-Johansen M, Edvardsen K: Tumor cell invasion and angiogenesis in the central nervous system. Curr Opin Oncol 9: 223-229, 1997
25. Stemmer-Rachamimov AO, Louis DN: Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 9: 230-234, 1997
26. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumours of the central nervous system. World Health Organization. In: International Histological Classification of Tumours. 2nd edn., Springer-Verlag, Berlin, Heidelberg, 1993
27. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 557-580, 1981
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
29. Mantel N: Evaluation of survival data and two new rank order statistics arising in this consideration. Cancer Chemother Rep 50: 163-170, 1966
30. Paganetti PA, Caroni P, Schwab MB: Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease. J Cell Biol 107: 2281-2291, 1988
31. Abe T, Mori T, Kohno K, Seiki M, Hayakawa T, Welgus HG, Hori S, Kuwano M: Expresion of 72kDa type IV collagenase and invasion activity of human glioma cells. Clin Exp Metastasis 12: 296-304, 1994
32. Boghaert ER, Chan SK, Zimmer C, Grobelny D, Galardy RE, Vanaman TC, Zimmer SG: Inhibition of collagenolytic activity relates to quantitative reduction of invasion in vitro in a c-Ha-ras transfected glial cell line. J Neuro-Oncol 21: 141-150, 1994
33. Lund-Johansen M, Rucklidge GJ, Milne G, Bjerkvig R: A metalloproteinase, capable of destroying cultured brain tissue isolated from rat glioma cells. Anticancer Res 11: 1001-1006, 1991
34. Nakagawa T, Kubota T, Kabuto M, Fujimoto N, Okada Y: Secretion of MMP-2 by malignant human glioma cell lines: implications for the growth and cellular invasion of the extra-cellular matrix. J Neuro-Oncol 28: 13-24, 1996
35. Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R: Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neuro-Oncol 18: 129-138, 1994
36. Rutka JT, Matsuzawa K, Hubbard SL, Fukuyama K, Becker LE, Stetler-Stevenson WG, Edwards DR, Dirks PB: Expression of TIMP-1, TIMP-2, 72- and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell line invasiveness. Int J Oncol 6: 877-884, 1995
37. Halaka AN, Bunning RAD, Bird CC, Gibson M, Reynolds JJ: Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg 59: 461-466, 1983
38. Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, Liotta LA, Nicolson GL, Stetler-Stevenson WG, Rao JS: Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 13: 57-62, 1995
39. Ring P, Johansson K, Höyhtyä M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer 76: 805-811, 1997
40. Russel DS, Rubinstein LJ: Pathology of Tumours of the Nervous System. London, Edward Arnold, edn., 5, 1989
41. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH, Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cell lines. Cancer Res 50: 2322-2329, 1990
42. DeClerck YA, Shimada H, Gonzalez-Gomez I, Raffel C: Tumoral invasion in the central nervous system. J Neuro-Oncol 18: 111-121, 1994
43. Laerum OD, Bjerkvig R, Steinsvåg SK, de Ridder L: Invâ siveness of primary brain tumors. Cancer Metastasis Rev 3: 223-236, 1984
44. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS: Prognostic significance of proteolytic enzymes in human brain tumors. J Neuro-Oncol 22: 101-110, 1994
45. Reith A, Rucklidge GJ: Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 186: 348-354, 1992
46. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the amniotic membrane: requirement for a proteinase caŝ cade. Cell 47: 487-498, 1986
47. Leon SP, Folkerth RD, Black PML: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77: 362-372, 1996
48. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock PJ, Rosenblum ML: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88: 513-520, 1998
49. Folkman J: What is the evidence that tumors are angiogenesis-dependent? JNCI 82: 4-6, 1990
50. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993
51. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. JNCI 87: 294-298, 1995
52. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157: 351-358, 1993
53. Takigawa M, Nishida Y, Suzuki F, Kishi JI, Yamashita K, Hayaka T: Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2) Biochem Biophys Res Commun 171: 1264-1271, 1990